Join
Live feed
·
PRReleasevia Quantisnow
Ionis Pharmaceuticals Inc. logo

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

ByQuantisnow·Wall Street's wire, on your screen.
IONS· Ionis Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IONS (Ionis Pharmaceuticals Inc.) and more on Quantisnow.